Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 12/2/13  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Daniel L. Simmons

Wrong Dr. Daniel L. Simmons?


Local Address: Utah, United States
Brigham Young University
100 Kimball Building
Rexburg, Idaho 83460
United States

Company Description: Founded in 1875, Brigham Young University has grown from a small pioneer academy to one of the world's largest private universities, where more than 29,000 students...   more

Employment History


  • PhD
  • Ph.D.
77 Total References
Web References
BYU's lawsuit says a chemistry professor, ..., 1 May 2012 [cached]
BYU's lawsuit says a chemistry professor, Daniel Simmons, discovered the genetic workings of the drug in the early 1990s. It accused Pfizer of violating a research agreement the school made with predecessor companies.
As part of the settlement, BYU plans to endow a Dan Simmons Chair in recognition of his lifelong work advancing human health.
"We are pleased to resolve this matter and the uncertainty of litigation and to be in a position to support Dr. Simmons' research efforts at BYU," Pfizer said in a brief statement.
The lawsuit asks for a jury ..., 18 Oct 2009 [cached]
The lawsuit asks for a jury trial in its claim that Pfizer and its predecessor companies, including Monsanto, unjustly took credit for and profited from the work of Daniel L. Simmons, a professor of biochemistry at BYU.
Simmons said in a statement that he looked forward to receiving proper credit for his work. "I appreciate the support of the university, and I'm grateful that the real story behind this research will come out," he said.
A Pfizer spokesman denied the accusations.
"Dr. Simmons played no role in the discovery of Celebrex, and the allegations raised by BYU and Dr. Simmons are baseless," said Pfizer spokesman Bryant Haskins, in a statement.
BYU maintains in the lawsuit that Simmons discovered the COX-2 enzyme and signed a contract with Monsanto to develop NSAIDs that would protect the stomach while tackling pain and swelling.
"Dan Simmons and BYU had a written contract with Monsanto to use his recent discovery of COX-2 to collaborate in development of a new aspirin-like drug," said Smart.
Our lawsuit says they took Dr. Simmons' findings and discoveries and went on to develop a blockbuster drug without him, which we believe violated the contract by sharing none of the credit or compensation."
The lawsuit asks that dozens of COX-2 related patents be corrected to reflect Simmons' role. "These patents were all based on the work of Dr. Simmons," the lawsuit says.
In at least two Monsanto patents, the lawsuit says, "Monsanto fraudulently misrepresented that its cell-testing systems were constructed using human or murine COX-1 or COX-2 fragments" from a Michigan company. "Dr. Simmons has recently learned," the complaint says, that the cell systems in at least one case "were made using the clones Dr. Simmons had provided Monsanto."
The lawsuit also claims that the drug company misrepresented to the Food and Drug Administration Monsanto's "true role" in the development of Celebrex.
At the time Monsanto and BYU entered into their agreement, Monsanto was trying to develop a steroid-like project and was testing compounds for NSAID properties only so it could eliminate them from consideration, the complaint says.
Haskins said Pfizer did acknowledge that Monsanto had a research agreement with Simmons and BYU, but when asked to what extent Simmons' research was used in the company's COX-2 project, Haskins said the company would not comment on pending litigation.
In 1998, pharmaceutical company Merck asked Simmons to testify in Monsanto's patent infringement suit against Merck, the BYU lawsuit says, and that's when Simmons learned that Monsanto was taking sole credit for the discovery of COX-2.
In another lawsuit with the University of Rochester, the BYU complaint says, Monsanto in a brief said that "Brigham Young's scientists were the first to identify methods of treatment using selective COX-2 inhibitors."
When BYU tried to resolve the issues with Monsanto, the lawsuit says, the company initially denied "even knowing who Dr. Simmons was. When confronted with the signed agreement," the complaint says, "Monsanto admitted to working with Dr. Simmons" but continued to deny working with them on a project to develop a COX-2 selective NSAID.
Vioxx case illustrates dual nature of drugs, 23 Dec 2004 [cached]
"This is where it all becomes murky," said Dr. Daniel Simmons, the director of the Cancer Research Center at Brigham Young University and a discoverer of the COX-2 enzyme.
"We think this year's run is ..., 6 Feb 2007 [cached]
"We think this year's run is going to be the best ever," said Dan Simmons, Director of the Cancer Research Center.
Delaware Health Sciences Alliance (DHSA) I PROFILES, 3 April 2014 [cached]
Daniel Simmons
Other People with the name "Simmons":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.